Wall Street analyst estimates for ProPhase Labs, Inc. (PRPH): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 0.50 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-16 | $2.05 | ||
| 2026-08-19 | $-0.22 | ||
| 2026-06-30 | $-0.43 | $-1.20 | +64.2% |
| 2026-04-14 | $-0.87 | $-1.20 | +27.5% |
| 2025-11-19 | $-1.60 | $-1.10 | -45.5% |
| 2025-08-13 | $-1.10 | $-1.50 | +26.7% |
| 2025-05-20 | $-1.20 | $-1.80 | +33.3% |
| 2025-03-31 | $-1.86 | $-0.24 | -675.0% |
Valuation Ratios
| Price / Book | -0.06 |
| EV / EBITDA | -1.31 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.0M | $9.9M | $13.1M | $9.9M | $14.5M | $79.0M | $122.6M | $44.4M | $6.8M | $4.3M |
| Cost of Revenue | $10.9M | $7.9M | $8.3M | $7.3M | $9.9M | $46.2M | $52.0M | $28.1M | $6.9M | $3.0M |
| Gross Profit | $10.1M | $1.9M | $4.8M | $2.6M | $4.6M | $32.8M | $70.7M | $16.2M | -$150000 | $1.4M |
| Research & Development | $575000 | $431000 | $398000 | $332000 | $633000 | $520000 | $652000 | $1.4M | $594000 | $107000 |
| Selling, General & Admin | $12.1M | $5.5M | $6.0M | $5.5M | $7.9M | $22.5M | $46.4M | $34.5M | $37.9M | $19.3M |
| Operating Expenses | $12.7M | $5.9M | $6.4M | $5.9M | $8.6M | $23.0M | $47.1M | $37.9M | $38.5M | $19.4M |
| Operating Income | -$2.7M | -$4.0M | -$1.6M | -$3.2M | -$4.0M | $9.8M | $23.6M | -$21.6M | -$38.6M | -$18.0M |
| EBITDA | -$3.4M | -$3.7M | -$1.3M | -$2.7M | -$1.5M | $11.4M | $28.7M | -$14.8M | -$32.3M | -$11.4M |
| Interest Expense | $213000 | $54000 | 0 | 0 | $295000 | $1.1M | $764000 | $1.3M | $3.4M | $6.9M |
| Pre-tax Income | -$2.9M | -$3.7M | -$1.5M | -$3.1M | -$2.3M | $5.3M | $22.9M | -$22.4M | -$42.3M | -$23.4M |
| Income Tax | $212000 | -$18.0M | $103000 | 0 | $12000 | -$968000 | $4.4M | -$6.0M | $7.2M | 0 |
| Net Income | -$2.9M | $41.8M | -$1.7M | -$3.1M | -$2.1M | $6.3M | $18.5M | -$16.8M | -$53.4M | -$14.7M |
| EPS | $-1.70 | $26.10 | $-1.50 | $-2.60 | $-2.00 | $4.10 | $11.70 | $-9.80 | $-26.10 | $-1.74 |
| EPS (Diluted) | $-1.70 | $25.90 | $-1.50 | $-2.60 | $-2.00 | $4.00 | $10.20 | $-9.80 | $-26.10 | $-1.74 |
| Shares Outstanding (Diluted) | $1.7M | $1.6M | $1.1M | $1.2M | $1.2M | $1.8M | $1.9M | $1.7M | $1.9M | $8.5M |
Price
| Price | $0.01 |
| Market Cap | $0M |
| Exchange | OTC |
| Country | US |
Related companies: ADAP · AEMD · ALUR · AYTU · BFRI · CODX · ERNA
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of PRPH: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks